Table 1 Characteristics of the participants analyzed in this study

241

182

59

51(46–57)

50(45–57)

52(47–57)

163/78

113/69

50/9§

32/209

19/163

13/46‡

Baseline

Follow-up

Baseline

Follow-up

Baseline

Follow-up

23.3(21.3–25.3)

23.2(21.3–25.4)

22.9(21.0–24.9)

23.0(20.9–25.0)

24.4(22.6–24.4)

24.2(22.8–26.0)

93(89–96)

94(90–97)†

92(89–95)

92(89–95)

95(91–97)

101(94–105)†

104(93–116)

106(92–119)†

102(91–113)

103(90–114)

114(103–123)

134(109–155)†

3.4(2.6–4.8)

3.6(2.8–5.1)

3.3(2.6–4.5)

3.4(2.7–4.6)

3.7(2.6–5.3)

4.4(3.6–5.8)†

19.3(12.3–29.6)

21.6(14.0–35.8)†

18.5(10.8–27.2)

19.5(13.4–32.2)

25.1(16.6–35.0)

31.9(19.9–49.5)†

12.8(9.3–18.8)

11.5(7.5–16.4)†

13.2(10.2–19.4)

12.4(9.3–17.3)

11.1(8.3–17.8)

7.3(5.3–11.0)†

0.400(0.378–0.421)

0.396(0.376–0.417)*

0.400(0.380–0.424)

0.401(0.381–0.422)

0.393(0.372–0.420)

0.377(0.363–0.391)†

0.29(0.21–0.38)

0.28(0.20–0.36)

0.30(0.22–0.39)

0.29(0.22–0.37)

0.28(0.19–0.40)

0.23(0.17–0.28)†

0.61(0.36–1.10)

0.63(0.40–1.03)

0.65(0.39–1.12)

0.69(0.45–1.12)

0.48(0.29–0.90)

0.52(0.29–0.91)

740.1(529.4–952.5)

753.2(571.3–1033.0)

755.5(561.7–967.4)

776.8(619.5–1030.3)

694.8(504.2–864.5)

638.2(448.7–869.8)

205.2(161.6–251.8)

209.5(174.1–263.2)

206.8(168.4–252.8)

211.0(182.2–267.8)

199.0(155.3–236.5)

188.8(146.0–237.1)

7.78(4.38–15.52)

6.89(3.48–12.06)

8.73(5.27–17.2)

8.25(5.18–15.23)

5.16(3.28–9.33)

3.24(2.09–5.72)†

3.27(2.87–3.88)

3.28(2.73–3.76)

3.41(2.93–3.97)

3.43(2.94–3.93)

3.04(2.65–3.65)

2.70(2.19–3.36)†

0.84(0.61–1.73)

0.96(0.64–1.31)

0.66(0.45–0.86)§

1.00(0.94–1.10)

1.00(0.96–1.05)

0.95(0.90–1.01)§

0.97(0.71–1.79)

1.00(0.79–1.31)

0.79(0.58–1.06)§

0.99(0.66–1.59)

0.99(0.68–1.58)

1.01(0.63–1.86)

1.02(0.78–1.65)

1.03(0.80–1.31)

0.98(0.68–1.44)

1.03(0.83–1.50)

1.03(0.84–1.23)

1.02(0.78–1.31)

0.88(0.45–1.61)

0.93(0.47–1.70)

0.68(0.37–1.27)‡

0.99(0.91–1.05)

1.01(0.95–1.06)

0.89(0.78–0.96)§

3.3(2.2–4.1)

3.4(2.1–4.1)

3.1(2.2–4.7)